Hu is among the experts concerned these practices could change under 23andMe or any new buyer. "In a time of financial vulnerability, companies such as pharmaceutical companies might see an opportunity to exploit the research benefits of the genetic data," Hu said, adding that they might try to renegotiate prior contracts to extract more data from the company. "Will the next company that buys 23andMe do that?," Hu said of its privacy policies.
In recent days, 23andMe has said it will try to find a buyer who shares its privacy values.